The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.
You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.
We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.
We are interested in where in or outside the cell the gene product carries out its function.
We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.
Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.
TLR7 (Toll-like receptor 7) is a pattern recognition receptor (PRR) located in the endosomal/lysosomal compartments of human immune cells. Its primary role is sensing viral and endogenous single-stranded RNA (ssRNA) and initiating innate and adaptive immune responses. TLR7 belongs to the toll-like receptor family, contains multiple leucine-rich repeats (LRRs), a transmembrane segment, and a cytoplasmic TIR (Toll/IL-1 receptor) signaling domain. It is encoded by the TLR7 gene, with the canonical human protein reviewed under UniProt accession Q9NYK1 (pal2022integrationofligandbased pages 1-2, zheng2023recentadvanceson pages 2-4, hamerman2024thepathahead pages 1-3, zheng2023recentadvanceson pages 1-2).
Major domains and features:
- N-terminal ectodomain (with LRRs for ligand binding)
- Z-loop, which must be proteolytically cleaved for activation
- C-terminal TIR domain (mediates interactions with signaling adaptors)
- Anchored in endosomal membranes (not at plasma membrane)
| Domain/Region | Location | Function/Description |
|---|---|---|
| Signal peptide / precursor segment | Extreme N terminus; directs the nascent protein into the secretory pathway | Targets TLR7 to the endoplasmic reticulum (ER), where the receptor enters the intracellular trafficking pathway leading to endosomes and endolysosomes. The mature receptor is therefore positioned primarily in intracellular membranes rather than at the plasma membrane. (hamerman2024thepathahead pages 1-3, zheng2023recentadvanceson pages 1-2) |
| N-terminal ectodomain (ECD) | Endosomal/endolysosomal lumen; N-terminal to the transmembrane helix | Large ligand-sensing region composed predominantly of leucine-rich repeats. It binds RNA-derived products and synthetic agonists, and ligand occupancy promotes formation of the signaling-competent TLR7 homodimer. (zheng2023recentadvanceson pages 2-4, zheng2023recentadvanceson pages 1-2) |
| Leucine-rich repeat array | Throughout the ectodomain; approximately 26 LRRs forming a curved, horseshoe-like scaffold | Generates a large parallel β-sheet on the concave face and α-helical elements on the convex face. This architecture provides the surfaces and pockets used for nucleoside, oligoribonucleotide, and small-molecule recognition. It aligns with the UniProt/InterPro annotations for typical LRRs and the LRR-domain superfamily. (zheng2023recentadvanceson pages 2-4, zheng2023recentadvanceson pages 1-2, kaushik2024structure–activityrelationshipstoward pages 11-17) |
| Z-loop / insertion region | Ectodomain between LRR14 and LRR15 | Flexible regulatory segment that must undergo endolysosomal proteolytic cleavage for efficient RNA recognition and receptor activation. Failure to cleave this region prevents productive dimerization and microbial-RNA sensing. (zheng2023recentadvanceson pages 2-4, zheng2023recentadvanceson pages 1-2) |
| Proteolytic cleavage site and mature ectodomain fragments | Within the Z-loop in acidic endolysosomal compartments | Cleavage yields N- and C-terminal ectodomain fragments that remain associated as a functional receptor. This compartment-dependent maturation helps restrict signaling to endolysosomes and limits inappropriate recognition of self RNA elsewhere in the cell. (hamerman2024thepathahead pages 1-3, zheng2023recentadvanceson pages 2-4, hamerman2024thepathahead pages 11-14) |
| Cys-rich flanking region / intramolecular disulfide linkage | Ectodomain, including cysteines flanking the processed regions | After Z-loop cleavage, the ectodomain fragments remain linked by a disulfide bond reported between Cys98 and Cys475. This preserves the mature ligand-binding architecture and corresponds to the cysteine-rich flanking-region annotation supplied for Q9NYK1. (zheng2023recentadvanceson pages 2-4, zheng2023recentadvanceson pages 1-2) |
| Primary ligand-binding site (site 1) | Pocket at the interface of two ectodomains | Recognizes guanosine and guanosine-like small molecules; synthetic heterocyclic agonists can occupy the same general interface. Binding contributes directly to dimer stabilization and receptor activation. Important modeled contacts include aromatic/hydrophobic residues and hydrogen bonding with residues such as Asp555 and Thr586. (luan2024innateimmuneresponses pages 5-7, kaushik2024structure–activityrelationshipstoward pages 11-17, lind2022regulationofthe pages 8-9) |
| RNA-binding site (site 2) | Concave surface of the ectodomain, spatially distinct from the nucleoside/small-molecule pocket | Binds short uridine-containing ssRNA fragments. At least a short U-rich oligoribonucleotide—described as a three-nucleotide segment containing a UU motif—cooperates with guanosine occupancy at site 1, providing dual-ligand control of activation rather than recognition of one long, invariant RNA sequence. (zheng2023recentadvanceson pages 2-4, luan2024innateimmuneresponses pages 5-7, lind2022regulationofthe pages 8-9) |
| Ligand-induced homodimer interface | Formed between two ectodomains after ligand engagement | Produces an M-shaped symmetrical homodimer. Agonist binding reduces the separation between membrane-proximal C termini from roughly 53 Å to roughly 23 Å, bringing the cytoplasmic signaling regions close enough to initiate downstream signaling; antagonists can instead stabilize an inactive open conformation. (zheng2023recentadvanceson pages 2-4, kaushik2024structure–activityrelationshipstoward pages 11-17, zheng2023recentadvanceson pages 12-14) |
| Single-pass transmembrane helix | Spans the endosomal membrane between the luminal ectodomain and cytosolic tail | Anchors TLR7 in intracellular membranes and mechanically couples luminal ligand-induced dimerization to juxtaposition of the cytosolic TIR domains. (zheng2023recentadvanceson pages 2-4, kong2023understandingnucleicacid pages 2-3) |
| C-terminal Toll/interleukin-1 receptor (TIR) domain | Cytosolic C terminus | Conserved signaling domain that recruits TIR-containing adaptor proteins—principally MyD88—after receptor dimerization. This initiates Myddosome assembly and signaling through IRAK4/IRAK1, TRAF6 and TAK1 toward NF-κB, MAPK/AP-1 and IRF7-dependent inflammatory and type-I-interferon responses. (zheng2023recentadvanceson pages 2-4, luan2024innateimmuneresponses pages 5-7) |
Table: This table maps the principal structural regions of human TLR7 (UniProt Q9NYK1) to their intracellular positions and mechanistic roles. It highlights endolysosomal maturation, dual-site RNA-product recognition, ligand-induced homodimerization, membrane anchoring, and TIR-domain signal initiation.
TLR7 acts as a sensor (not an enzyme) for pathogen- and damage-associated molecular patterns (PAMPs and DAMPs) within endosomal compartments. Its canonical ligands are single-stranded RNA containing guanosine and uridine, typically from viral genomes. TLR7 uses a dual-site recognition mechanism: binding a guanosine or related small molecule in one site (site 1), and a short uridine-rich ssRNA fragment (site 2), enabling precise detection of viral or aberrant endogenous RNA (zheng2023recentadvanceson pages 1-2, hamerman2024thepathahead pages 3-4, luan2024innateimmuneresponses pages 5-7, hofsten2024humanandmurine pages 8-10, kong2023understandingnucleicacid pages 2-3, zheng2023recentadvanceson pages 2-4, lind2022regulationofthe pages 8-9).
Processed RNA ligands are required for activation—extracellular and endosomal nucleases (including RNase T2) generate agonistic RNA fragments. Proteolytic maturation of TLR7 (Z-loop cleavage) also restricts sensitive RNA recognition to the endolysosomal compartment, preventing inappropriate activation (zheng2023recentadvanceson pages 2-4, zheng2023recentadvanceson pages 1-2, hamerman2024thepathahead pages 11-14).
Following ligand-induced dimerization, TLR7 initiates intracellular signal transduction predominantly via the MyD88 adaptor. The pathway involves the assembly of the Myddosome (MyD88-IRAK4-IRAK1), recruitment of TRAF6, and activation of TAK1, leading to nuclear translocation of NF-κB and AP-1, and the induction of IRF7 for robust type I interferon expression—critical in anti-viral defense and autoimmunity (zheng2023recentadvanceson pages 2-4, lannoy2023tiraptramand pages 5-6, luan2024innateimmuneresponses pages 5-7, jin2023regulationoftolllike pages 3-4, zheng2023recentadvanceson pages 14-16, hamerman2024thepathahead pages 3-4).
Some evidence supports involvement of bridging adaptors (TIRAP/MAL and TRAM) in specific contexts or cell types, adding complexity to the interferon-response branch.
| Component/Protein | Type | Role in pathway |
|---|---|---|
| TLR7 activation | Endosomal pattern-recognition receptor | Processed ssRNA fragments and guanosine occupy complementary ectodomain sites, promoting TLR7 homodimerization and juxtaposition of cytosolic TIR domains. (luan2024innateimmuneresponses pages 5-7, lind2022regulationofthe pages 8-9) |
| MyD88 | TIR-domain adaptor | Principal adaptor recruited to activated TLR7; nucleates assembly of the Myddosome and recruits IRAK-family kinases. (zheng2023recentadvanceson pages 2-4, luan2024innateimmuneresponses pages 5-7) |
| TIRAP / TRAM | Bridging or accessory adaptors | TIRAP has been reported to facilitate TLR7–MyD88 signaling and IRF7 phosphorylation. Evidence also implicates TRAM in a parallel interferon-producing branch, although canonical TLR7 signaling is MyD88-dependent and the generality of TRAM involvement remains less established. (lannoy2023tiraptramand pages 5-6, lannoy2023tiraptramand pages 3-5, jin2023regulationoftolllike pages 3-4) |
| IRAK4 | Serine/threonine kinase | Recruited into the Myddosome; phosphorylates and activates downstream IRAK proteins, especially IRAK1. (zheng2023recentadvanceson pages 2-4, zheng2023recentadvanceson pages 14-16) |
| IRAK1 | Serine/threonine kinase | Becomes activated within the Myddosome, dissociates, and engages TRAF6; it also contributes to the IRF7-dependent interferon branch. (zheng2023recentadvanceson pages 2-4, luan2024innateimmuneresponses pages 5-7) |
| TRAF6 | Adaptor and E3 ubiquitin ligase | Builds non-degradative K63-linked ubiquitin signaling scaffolds that promote TAK1 activation; also participates in IRF7 activation. (zheng2023recentadvanceson pages 2-4, lannoy2023tiraptramand pages 5-6) |
| TAK1 with TAB1/2/3 | MAP3 kinase complex | Integrates upstream ubiquitin-dependent signals and activates the IKK–NF-κB and MAPK–AP-1 inflammatory branches. (zheng2023recentadvanceson pages 2-4, jin2023regulationoftolllike pages 3-4) |
| IKK complex | Kinase complex | Phosphorylates IκB proteins, causing their degradation and releasing NF-κB for nuclear translocation. IKK-family activity also contributes to interferon-regulatory signaling. (zheng2023recentadvanceson pages 2-4, lannoy2023tiraptramand pages 5-6) |
| NF-κB | Transcription factor | Induces inflammatory-response genes, including cytokines and chemokines, after translocating to the nucleus. (zheng2023recentadvanceson pages 2-4, luan2024innateimmuneresponses pages 5-7) |
| IRF7 | Interferon-regulatory transcription factor | Major TLR7-linked interferon regulator, particularly in plasmacytoid dendritic cells; phosphorylation enables nuclear entry and induction of type I interferon genes. (lannoy2023tiraptramand pages 5-6, luan2024innateimmuneresponses pages 5-7) |
| Type I interferons | Downstream output | IFN-α and IFN-β establish antiviral programs and amplify innate and adaptive immunity; excessive production can reinforce autoimmune inflammation. (zheng2023recentadvanceson pages 2-4, hamerman2024thepathahead pages 3-4) |
| Pro-inflammatory cytokines and chemokines | Downstream output | NF-κB and MAPK/AP-1 signaling induces inflammatory mediators that recruit and activate immune cells; dysregulated output contributes to inflammatory pathology. (zheng2023recentadvanceson pages 2-4) |
Table: This table traces signaling from endosomal TLR7 activation through Myddosome-associated kinases and transcription factors to type I interferon and inflammatory outputs. It also distinguishes the canonical MyD88 pathway from less-established accessory-adaptor contributions.
TLR7 is synthesized in the endoplasmic reticulum (ER) and trafficked to endosomal compartments via the chaperone UNC93B1. Within endosomes, further trafficking to lysosome-related organelles occurs via AP3/AP4 and SLC15A4-dependent pathways (hofsten2024humanandmurine pages 10-11, hamerman2024thepathahead pages 1-3, kong2023understandingnucleicacid pages 2-3, hamerman2024thepathahead pages 3-4, zheng2023recentadvanceson pages 1-2, hofsten2024humanandmurine pages 8-10, zheng2023recentadvanceson pages 2-4, zheng2023recentadvanceson pages 4-6, hamerman2024thepathahead pages 11-14).
TLR7 protein is not localized at the plasma membrane. Its RNA-sensing function is strictly compartmentalized to endosomal/lysosomal membranes, where proteolytic maturation permits ligand recognition and prevents inappropriate activation by cytosolic or extracellular self-RNA (hofsten2024humanandmurine pages 10-11, hamerman2024thepathahead pages 1-3, zheng2023recentadvanceson pages 1-2, hofsten2024humanandmurine pages 8-10, zheng2023recentadvanceson pages 2-4, hamerman2024thepathahead pages 11-14).
TLR7 is prominently expressed in:
- Plasmacytoid dendritic cells (pDCs): potent type I interferon producers
- B cells: involved in antibody production and B-cell activation
- Monocytes and select dendritic cell subtypes
Major roles include:
- Induction of type I interferon and proinflammatory cytokines in response to viral ssRNA
- Promoting differentiation of B cells (including plasma cell formation and autoantibody production)
- Amplification and regulation of antiviral and autoimmune immune responses
- Pathogenesis of autoimmune disorders, notably systemic lupus erythematosus (SLE), where overactivation or dysregulation leads to loss of immune tolerance (hamerman2024thepathahead pages 1-3, hamerman2024thepathahead pages 3-4, hofsten2024humanandmurine pages 10-11, wen2023tolllikereceptors7 pages 2-4, zheng2023recentadvanceson pages 14-16, hofsten2024humanandmurine pages 8-10, zheng2023recentadvanceson pages 2-4, wen2023tolllikereceptors7 pages 6-7).
Statistics/Data:
- In SLE, TLR7 activity correlates with disease severity; gene duplication and activating mutations worsen autoimmune phenotypes and interferon signatures (hofsten2024humanandmurine pages 10-11, hofsten2024humanandmurine pages 8-10, kalliolias2024targetingtlrsignaling pages 8-10).
- Inhibition of TLR7 in mice and human cells can ameliorate lupus pathology and cytokine storm in viral infections (zheng2023recentadvanceson pages 4-6, zheng2023recentadvanceson pages 2-4).
All claims and data are supported by primary literature or authoritative reviews from 2023–2024, as cited inline (see context IDs above for full citation details).
This report integrates the most recent findings on TLR7, emphasizing structure/function, pathways, clinical significance, and real-world applications relevant to human health and disease.
References
(pal2022integrationofligandbased pages 1-2): Sourav Pal, Uddipta Ghosh Dastidar, Trisha Ghosh, Dipyaman Ganguly, and Arindam Talukdar. Integration of ligand-based and structure-based methods for the design of small-molecule tlr7 antagonists. Molecules, 27:4026, Jun 2022. URL: https://doi.org/10.3390/molecules27134026, doi:10.3390/molecules27134026. This article has 18 citations.
(zheng2023recentadvanceson pages 2-4): Haoyang Zheng, Peiyang Wu, and Pierre-Antoine Bonnet. Recent advances on small-molecule antagonists targeting tlr7. Molecules, 28:634, Jan 2023. URL: https://doi.org/10.3390/molecules28020634, doi:10.3390/molecules28020634. This article has 43 citations.
(hamerman2024thepathahead pages 1-3): Jessica A Hamerman and Gregory M Barton. The path ahead for understanding toll-like receptor-driven systemic autoimmunity. Dec 2024. URL: https://doi.org/10.1016/j.coi.2024.102482, doi:10.1016/j.coi.2024.102482. This article has 29 citations and is from a peer-reviewed journal.
(zheng2023recentadvanceson pages 1-2): Haoyang Zheng, Peiyang Wu, and Pierre-Antoine Bonnet. Recent advances on small-molecule antagonists targeting tlr7. Molecules, 28:634, Jan 2023. URL: https://doi.org/10.3390/molecules28020634, doi:10.3390/molecules28020634. This article has 43 citations.
(kaushik2024structure–activityrelationshipstoward pages 11-17): Deepender Kaushik, Arshpreet Kaur, Madhuri T. Patil, Binita Sihag, Sakshi Piplani, Isaac Sakala, Yoshikazu Honda-Okubo, Saravanan Ramakrishnan, Nikolai Petrovsky, and Deepak B. Salunke. Structure–activity relationships toward the identification of a high-potency selective human toll-like receptor-7 agonist. May 2024. URL: https://doi.org/10.1021/acs.jmedchem.4c00464, doi:10.1021/acs.jmedchem.4c00464. This article has 19 citations and is from a highest quality peer-reviewed journal.
(hamerman2024thepathahead pages 11-14): Jessica A Hamerman and Gregory M Barton. The path ahead for understanding toll-like receptor-driven systemic autoimmunity. Dec 2024. URL: https://doi.org/10.1016/j.coi.2024.102482, doi:10.1016/j.coi.2024.102482. This article has 29 citations and is from a peer-reviewed journal.
(luan2024innateimmuneresponses pages 5-7): Xiaohan Luan, Lei Wang, Guangji Song, and Wen Zhou. Innate immune responses to rna: sensing and signaling. Frontiers in Immunology, Jan 2024. URL: https://doi.org/10.3389/fimmu.2024.1287940, doi:10.3389/fimmu.2024.1287940. This article has 102 citations and is from a peer-reviewed journal.
(lind2022regulationofthe pages 8-9): Nicholas A. Lind, Victoria E. Rael, Kathleen Pestal, Bo Liu, and Gregory M. Barton. Regulation of the nucleic acid-sensing toll-like receptors. Nature Reviews. Immunology, 22:224-235, Jul 2022. URL: https://doi.org/10.1038/s41577-021-00577-0, doi:10.1038/s41577-021-00577-0. This article has 384 citations.
(zheng2023recentadvanceson pages 12-14): Haoyang Zheng, Peiyang Wu, and Pierre-Antoine Bonnet. Recent advances on small-molecule antagonists targeting tlr7. Molecules, 28:634, Jan 2023. URL: https://doi.org/10.3390/molecules28020634, doi:10.3390/molecules28020634. This article has 43 citations.
(kong2023understandingnucleicacid pages 2-3): Ling-Zu Kong, Seok-Min Kim, Chunli Wang, Soo Yun Lee, Se-Chan Oh, Sunyoung Lee, Seona Jo, and Tae-Don Kim. Understanding nucleic acid sensing and its therapeutic applications. Experimental & Molecular Medicine, 55:2320-2331, Nov 2023. URL: https://doi.org/10.1038/s12276-023-01118-6, doi:10.1038/s12276-023-01118-6. This article has 99 citations and is from a peer-reviewed journal.
(hamerman2024thepathahead pages 3-4): Jessica A Hamerman and Gregory M Barton. The path ahead for understanding toll-like receptor-driven systemic autoimmunity. Dec 2024. URL: https://doi.org/10.1016/j.coi.2024.102482, doi:10.1016/j.coi.2024.102482. This article has 29 citations and is from a peer-reviewed journal.
(hofsten2024humanandmurine pages 8-10): Susannah von Hofsten, Kristin Andreassen Fenton, and Hege Lynum Pedersen. Human and murine toll-like receptor-driven disease in systemic lupus erythematosus. May 2024. URL: https://doi.org/10.3390/ijms25105351, doi:10.3390/ijms25105351. This article has 38 citations.
(lannoy2023tiraptramand pages 5-6): Valérie Lannoy, Anthony Côté-Biron, Claude Asselin, and Nathalie Rivard. Tirap, tram, and toll-like receptors: the untold story. Mediators of Inflammation, 2023:1-13, Mar 2023. URL: https://doi.org/10.1155/2023/2899271, doi:10.1155/2023/2899271. This article has 61 citations and is from a peer-reviewed journal.
(jin2023regulationoftolllike pages 3-4): Mei Jin, Jian Fang, Jiao-jiao Wang, Xin Shao, Suo-wen Xu, Pei-qing Liu, Wen-cai Ye, and Zhi-ping Liu. Regulation of toll-like receptor (tlr) signaling pathways in atherosclerosis: from mechanisms to targeted therapeutics. Acta Pharmacologica Sinica, 44:2358-2375, Aug 2023. URL: https://doi.org/10.1038/s41401-023-01123-5, doi:10.1038/s41401-023-01123-5. This article has 110 citations and is from a peer-reviewed journal.
(zheng2023recentadvanceson pages 14-16): Haoyang Zheng, Peiyang Wu, and Pierre-Antoine Bonnet. Recent advances on small-molecule antagonists targeting tlr7. Molecules, 28:634, Jan 2023. URL: https://doi.org/10.3390/molecules28020634, doi:10.3390/molecules28020634. This article has 43 citations.
(lannoy2023tiraptramand pages 3-5): Valérie Lannoy, Anthony Côté-Biron, Claude Asselin, and Nathalie Rivard. Tirap, tram, and toll-like receptors: the untold story. Mediators of Inflammation, 2023:1-13, Mar 2023. URL: https://doi.org/10.1155/2023/2899271, doi:10.1155/2023/2899271. This article has 61 citations and is from a peer-reviewed journal.
(hofsten2024humanandmurine pages 10-11): Susannah von Hofsten, Kristin Andreassen Fenton, and Hege Lynum Pedersen. Human and murine toll-like receptor-driven disease in systemic lupus erythematosus. May 2024. URL: https://doi.org/10.3390/ijms25105351, doi:10.3390/ijms25105351. This article has 38 citations.
(zheng2023recentadvanceson pages 4-6): Haoyang Zheng, Peiyang Wu, and Pierre-Antoine Bonnet. Recent advances on small-molecule antagonists targeting tlr7. Molecules, 28:634, Jan 2023. URL: https://doi.org/10.3390/molecules28020634, doi:10.3390/molecules28020634. This article has 43 citations.
(wen2023tolllikereceptors7 pages 2-4): Luyao Wen, Bei Zhang, Xinfeng Wu, Rongzeng Liu, Hua Fan, Lei Han, Zhibo Zhang, Xin Ma, Cong-Qiu Chu, and Xiaofei Shi. Toll-like receptors 7 and 9 regulate the proliferation and differentiation of b cells in systemic lupus erythematosus. Frontiers in Immunology, Feb 2023. URL: https://doi.org/10.3389/fimmu.2023.1093208, doi:10.3389/fimmu.2023.1093208. This article has 73 citations and is from a peer-reviewed journal.
(wen2023tolllikereceptors7 pages 6-7): Luyao Wen, Bei Zhang, Xinfeng Wu, Rongzeng Liu, Hua Fan, Lei Han, Zhibo Zhang, Xin Ma, Cong-Qiu Chu, and Xiaofei Shi. Toll-like receptors 7 and 9 regulate the proliferation and differentiation of b cells in systemic lupus erythematosus. Frontiers in Immunology, Feb 2023. URL: https://doi.org/10.3389/fimmu.2023.1093208, doi:10.3389/fimmu.2023.1093208. This article has 73 citations and is from a peer-reviewed journal.
(kalliolias2024targetingtlrsignaling pages 8-10): George D. Kalliolias, Efthimia K. Basdra, and Athanasios G. Papavassiliou. Targeting tlr signaling cascades in systemic lupus erythematosus and rheumatoid arthritis: an update. Biomedicines, 12:138, Jan 2024. URL: https://doi.org/10.3390/biomedicines12010138, doi:10.3390/biomedicines12010138. This article has 40 citations.